Sandoz patent dispute ends: Sandoz stock pre-market at EUR 76.85
Published on 10/14/2026 at 08:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCourt filing and trading setup
- Amneal and Sandoz Group AG agreed on October 13, 2026, to end three patent lawsuits.
- Sandoz stock traded pre-market at EUR 76.85 at 8:25 a.m. CEST on October 14, 2026, at Lang & Schwarz.
- The dispute concerned proposed copies of the Parkinson’s treatment Crexont.
Amneal and Sandoz Group AG agreed on October 13, 2026, to end a patent-infringement dispute over proposed copies of Crexont, a Parkinson’s disease treatment, according to Bloomberg Law. The parties agreed to dismiss without prejudice all claims, counterclaims and affirmative defenses in three lawsuits filed in 2025.
Pre-market price
Sandoz stock traded pre-market at EUR 76.85 at 8:25 a.m. CEST on October 14, 2026, according to Lang & Schwarz. The bid was EUR 76.58 and the ask was EUR 77.12. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Sandoz stock.
What matters today
The October 13, 2026, court filing involved three lawsuits concerning proposed copies of Crexont. A Barclays report dated October 13, 2026, maintained a Buy rating and cited a CHF 93.00 price target, according to The Globe and Mail. The dispute stems from suits filed in January, June and November 2025.
Market context: Market report SMI.
